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Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of
the gastrointestinal apparatus, of which ulcerative colitis andCrohn’s disease are the commonest forms.This disease has a significant
prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs
approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that
in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside
other immune-modifying agents.
1. Introduction
Inflammatory bowel disease (IBD) is an idiopathic disease
caused by a dysregulated immune response to host intesti-
nal microflora and is comprised of two major disorders:
ulcerative colitis (UC), which is limited to the colon, and
Crohn’s disease (CD), which can affect any segment of the
gastrointestinal tract. Both are chronic inflammatory con-
dition characterised by relapsing and remitting episodes of
inflammation, which are transmural in CD and limited to
the mucosal layer of the colon in UC [1, 2]. In the clinical
practice, both UC and CD are typically classified as mild
to moderate, moderate to severe, and severe to fulminant.
Whereas the ultimate cause of IBD remains to be elucidated, a
combination of several factors, such as genetic predisposition,
environmental factors, and dysfunctions of the immune
system, contributes significantly to the development of this
disease. Patients with IBD are at increased risk for colorectal
cancer (CRC) and should undergo specific screening with
colonoscopy according to disease extent and duration [3].
The principal aims of the pharmacological treatment of
IBD are inducing and maintaining the remission, obtaining
mucosal repair, avoiding the surgical resection, and reducing
the development of cancer as a result of chronic inflamma-
tion. The therapy of mild-to-moderate IBD depends on the
location and degree of severity of the disease as well as patient
acceptability and consists of oral or rectal therapies used
individually or in combination. Severe or fulminant disease
requires hospitalisation and intensive parenteral therapy [4].
Five-aminosalicylic acid (5-ASA) (mesalamine or mesal-
azine) and its derivatives (i.e., balsalazide, olsalazine, and
sulfasalazine) are anti-inflammatory drugs indicated for the
treatment of IBD. In particular, 5-ASA agents are the core
therapy for UC and are recommended by the “American
College of Gastroenterology, ulcerative colitis practice guide-
lines” for both induction and maintenance of remission in
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patients with mild-to-moderate UC [5]. More than 88% of all
UC patients receive treatment with 5-ASA in USA as well as
in Europe [6].The use of 5-ASAdrugs for CD remains instead
controversial: a recentmeta-analysis found that 5-ASAs taken
as a group were superior to placebo for the induction of
remission, but no significant benefit in remission rates was
observed when only trials using 5-ASA were examined [7].
Additionally, no benefit was observed in the maintenance of
remission compared with placebo [7].
2. Intracellular Mechanisms Coupled to 5-ASA
Actions in Intestine Cells
A large body of experimental data shows that 5-ASA mod-
ulates multiple but not mutually exclusive pathways in the
intestine [8, 9]where it supposedly acts locally on themucosa.
Since 5-ASA has a similar structure to acetyl-salicylic acid,
it shares molecular targets, interfering with inflammation
and proliferation, similar to those of aspirin and other non-
steroidal anti-inflammatory drugs.
Five-ASA was initially shown to downregulate the indu-
cible cyclooxygenase/prostaglandin E2 (COX-2/PGE2) sig-
nalling in mucosa inflammatory cells [10, 11]. Later, 5-ASA
targeting of COX-2 was also demonstrated in intestine cells.
In particular, both basal and tumour necrosis factor (TNF-𝛼)/
interleukin- (IL-) 1𝛽-induced COX-2 expressions are inhib-
ited by 5-ASA thus reducing PGE2 synthesis [12], although
mechanisms other than COX-2 modulation have also been
suggested [12, 13]. Generally 5-ASA decreases the nuclear
factor 𝜅B (NF-𝜅B) activity induced by TNF-𝛼, modulating
the NF-𝜅B inhibitor, I𝜅B𝛼 [14–17], as well as the NF-𝜅B
transcriptional activity induced by IL-1, although it does
prevent neither IL-1-induced I𝜅B𝛼 degradation nor IL-1-
induced nuclear translocation ofNF-𝜅B familymembers [18].
Five-ASA was also found to increase 𝛽-catenin expres-
sion/phosphorylation and the expression of 𝜇-protocadherin
in intestine cells while reducing the expression of Wnt/𝛽-
catenin target genes and the activity of the protein phos-
phatase 2A [19–22].
More importantly, evidence is also accumulating suggest-
ing a key role of peroxisome proliferator-activated receptor
𝛾 (PPAR-𝛾) in mediating the anti-inflammatory effects of
5-ASA. This transcription factor, belonging to the nuclear
hormone receptor superfamily, modulates the inflammatory
response of monocytes and macrophages by inhibiting
the production of nitric oxide and macrophage-derived
cytokines such as TNF-𝛼 and IL-1 and IL-6 [23]. In particular,
5-ASA enhances PPAR-𝛾 expression/activity in intestine cells
and promotes its translocation from the cytoplasm to the
nucleus [22, 24, 25]. This is followed by the induction of the
tumour suppressor gene PTEN, the activation of caspases 8
and 3, and the inhibition of antiapoptotic proteins [22, 25]. By
promoting PPAR-𝛾 nuclear translocation 5-ASA also reduces
NF-𝜅B activation, increases the expression of I𝜅B𝛼, restores
STATs 1 and 3 protein concentrations, and reduces the expres-
sion of TNF-𝛼, monocyte chemotactic protein-1, and the
inducible nitric oxide synthase [17]. The importance of the 5-
ASA to PPAR-𝛾 signalling is clearly shown in experiments in
which 5-ASA inhibition of growth of colon cancer xenografts
is prevented by PPAR-𝛾 antagonists [26]. Interestingly 5-ASA
was found to normalise both PPAR-𝛾 and heterodimer ret-
inoid X receptor 𝛼 expression after irradiation [17].
Despite the relevance of the 5-ASA to PPAR-𝛾 signalling
this pathway cannot explain all the effects of 5-ASA such that
additional mechanisms have been proposed to be involved in
the antiproliferative role of this drug [25]. Indeed, in intestine
cells, 5-ASA also suppresses epidermal growth factor receptor
phosphorylation/activation, likely through the modulation
of the protein tyrosine phosphatases Src homology 2 [27].
In addition, the expression of 𝛽2-adrenoreceptor and 𝛽-
arrestin 2 was found to be increased after 5-ASA treatment,
suggesting an involvement of adrenergic receptors signalling
in 5-ASA effects [16]. Recently, 5-ASA was shown to induce
membranous expression of E-cadherin and increase cell
adhesion through inhibition of p-21 activated kinase-1 and
modulation of N-glycosylation [21, 28]. Finally, 5-ASA was
found to interfere also with the mitogen activated protein
kinase and phosphatidylinositol-4,5-bisphosphate 3-kinase/
Akt pathways [21, 22] confirming further the pleiotropic
mechanism of action of this drug.
3. Pharmacogenetics
Five-ASA is rapidly adsorbed and extensively acetylated
to N-acetyl-5-ASA by the N-acetyltransferase 1 enzyme in
intestinal epithelial cells and the liver [29]. Clinical evidence
indicates the presence of a significant interindividual variabil-
ity in terms of clinical response and safety to 5-ASA; it would
be important to understand in full this variability to allow
predicting patients who will either not respond or experience
adverse events [7, 30, 31]. A hypothesis that may explain these
clinical aspects is the presence of significant interindividual
variability in drug acetylation. The first observation of this
phenomenon was reported over 45 years ago, in patients
treated with isoniazid for tuberculosis [32, 33] in which
population were classified as slow and rapid acetylators [34],
based on the genetic variation within the N-acetyltransferase
genes (NAT) [34, 35].
Two isoenzymes, NAT1 and NAT2, have been identified
in humans and share overlapping as well as specific aryl-
amine substrates. The genes for both NAT1 and NAT2 are
located on chromosome 8p22. Several variant alleles of the
NAT1 gene have been described. A number of these are
functional and result in a reduced N and/or O-acetylation
(NAT∗14A, NAT1∗14B, NAT1∗17, NAT1∗19, and NAT1∗22)
[36–38]. Eleven single nucleotide polymorphisms (SNPs) in
the NAT2 gene result in 25 different alleles in humans [32,
34], several of which are associated with a slow acetylating
phenotype. Such phenotype is common, with over 50% of
Caucasian being slow acetylators [39]. Less frequent variants
include the NAT2∗12B, which is associated with high NAT2
expression and a fast acetylating phenotype [32, 35, 40].
The high frequencies of rapid and slow acetylators in the
general population, alongside the potential effects of these
SNPs on 5-ASA therapy, have suggested a possible explana-
tion for the variability in drug safety and response observed
in IBD patients [41]. Patients with a rapid acetylator genotype
for NAT1 could potentially experience a decreased efficacy
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of 5-ASA, while an increased efficacy could potentially be
observed in slow acetylators for NAT1.
SNPswithinNAT genesmay also play a role as risk factors
for sulfasalazine toxicity. Sulfasalazine is a prodrug that is
metabolised in the colonic lumen to 5-ASA and sulfapyridine.
Sulfapyridine is responsible for most of the side effects that
occur with sulfasalazine [39]. As sulfapyridine is inactivated
in the liver by NAT2, slow acetylators could be at higher
risk of toxicity [41]. Ricart and colleagues evaluated these
concerns in an analysis on a cohort of patients with UC [41].
The analysis was carried out by enrolling 77 patients with
UC and was aimed at evaluating the correlation between the
most frequent polymorphisms for NAT1 and NAT2 (13 and
17, resp.) and clinical response to 5-ASA and sulfasalazine.
The authors found no relationship between NAT1 genotype
and response to 5-ASA or sulfasalazine. Additionally, no
relationship between NAT2 genotype and toxicity to sul-
fasalazine was observed. Hausmann and colleagues achieved
a similar conclusion by considering NAT1 genotype and
clinical response in a cohort of 78 patients with UC [42].
These analyses indicate that, at variance with 5-ASA, NAT1/2
SNPs are unlikely to determine significant effects on 5-ASA
and sulfasalazine therapy [39, 43–49].
4. Pharmacovigilance
Five-ASA is generally well tolerated and the most common
side effects include headache, nausea, and abdominal pain
[30]. Clinical trials showed that the proportion of patients
treated with 5-ASA and experiencing adverse events was
similar to the one observed in placebo-treated patients [31].
Watery diarrhoea occurs in up to 8% of patients taking
oral preparations. Diarrhoea is usually mild and occurs at
the initiation of therapy. Patients generally report that this
condition resolves in 4 to 8 weeks, due to the ability of the
colon to adapt to an elevated fluid load secondary to increased
absorption [30, 31, 50].
Reports from postmarketing surveillance studies high-
lighted several cases of serious and nonserious adverse events
temporally correlated with 5-ASA therapy, including nephro-
toxicity, pancreatitis, respiratory failure, white cell aplasia,
and myocarditis [51–59].
A French pharmacovigilance study of 5-ASA reported
between 6.6 and 9.0 adverse events per million days of
treatment, including cases of pancreatitis, hepatitis, haema-
tological disturbances, and pericarditis [60]. Another study
identified 393 and 514 adverse events per million prescrip-
tions for 5-ASA and sulfasalazine, respectively, over an 8-
year interval [61]. The odds ratio for any adverse event on
sulfasalazine (relative to 5-ASA) was 1.31 (95% confidence
interval, 1.22–1.40). However, this risk varied depending
on the adverse event. Nephrotoxicity and pancreatitis were
significantly more likely to be reported with 5-ASA, whereas
haematological disturbances occurred more frequently with
sulfasalazine [61].These latter findings were criticised for sev-
eral reasons and subsequent studies andmeta-analyses found
an adverse event profile similar to that of the placebo [62–64].
Finally, approximately 3% of patients on oral preparations
have a paradoxical worsening of their colitis symptoms and
should be considered allergic to 5-ASAs. Drug should be
withdrawn and 5-ASAs should no longer be used [31].
4.1. Nephrotoxicity. Renal impairment represents one of the
most debated adverse reactions attributed to 5-ASA [65–74].
A review of published clinical trials concluded that renal
impairment might occur in up to one in 100 patients treated
with this drug. Clinically significant impairment did not
occur in any of the 500 patients for whomdata were available.
The incidence of clinically significant interstitial nephritiswas
estimated to be less than one in every 500 patients treated
when serum creatinine is monitored regularly [75]. Yet, 5-
ASA can cause interstitial nephritis. This includes reports of
IBD patients in which renal function deteriorated during 5-
ASA treatment and ameliorated after therapy discontinuation
[75, 76]. A case of positive de- and rechallenge (i.e., a ther-
apy discontinuation leading to improvement and therapy
resuming leading to subsequent clinical deterioration) was
also described [77]. The nephrotoxicity of 5-ASA was also
shown in animal models [68]. The structural similarity of 5-
ASA to drugs with well-documented nephrotoxic potential
lends further support to the hypothesis that this drug initiates
the interstitial inflammation in patients with IBD [68]. The
absence of a clear relationship between 5-ASA dose and
the risk of nephrotoxicity suggests that this complication is
idiosyncratic [67]. A significant dilemma in the definition
of causality association between 5-ASA and nephrotoxicity is
because IBD itself can cause renal dysfunction. Patients with
IBD may have extraintestinal manifestations of the disease
involving the kidney, such as stones and amyloidosis. Addi-
tionally, nonspecific morphological changes in the glomeruli
of patients with IBD may occur [78]. It has been calculated
that approximately 10% of the patients with 5-ASA nephro-
toxicity will develop end-stage renal disease, emphasising the
need for timely recognition of renal impairment and prompt
discontinuation of 5-ASA treatment of affected patients [5].
Thus, many authors agree on performing a monitoring of
renal function by serum creatinine measurements, although
the optimal schedule remains to be established and there
is no evidence that such screening or monitoring improves
patient outcomes [5]. A recent survey indicates that gastroen-
terologists tend to monitor renal function in IBD patients on
5-ASA, suggesting that this screening programme is widely
accepted among clinicians [74].
4.2. Acute Pancreatitis. Acute pancreatitis (AP) is an inflam-
matory disease of the pancreas characterised by severe acute
upper abdominal pain and elevated blood levels of serum
amylase and/or lipase [79]. A variety of medications are
listed among the aethiological factors for AP in the general
population after gallstones and alcoholism [80–83]. The
mechanisms of drug induced AP are not always clear but
they have been proposed to include direct toxicity, hypersen-
sitivity, secondary hyperlipidaemia, or hypercalcaemia [79].
More than one mechanism may be responsible for each
individual case. While it is difficult to establish a causal role
for some medications in the pathogenesis of AP [64, 84],
several cases of AP following therapy with 5-ASA have been
reported so far [85–90]. A suspected mechanism of such
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reaction was the similarity of the sulfonamide component to
thiazide diuretics, an established cause of AP. However, with
the use of 5-ASA medications, which lack the sulfonamide
component, pancreatitis still occurs. Another interesting
hypothesis to explain the mechanism of 5-ASA-induced
pancreatitis is the local effect of 5-ASA that may increase
pancreatic duct permeability [91]. Analysis of the reports
received by the manufacturer and by the USA Food and
Drug Administration adverse event report database indicates
disproportionality in the number of reports for pancreatitis
with Multi Matrix System and controlled-release 5-ASA
[92]. Such disproportion suggests that the drug delivery
mechanism is associated with variation of AP risk in IBD
patient, although pharmacoepidemiological study to confirm
this aspect formally is still lacking [92].
4.3. Myocarditis. Classic myocarditis refers to an inflam-
mation of the heart muscle caused by a variety of triggers
including infections, drugs, and autoimmune diseases [93].
Cardiac disease may develop in Crohn’s patients either as
a disease extraintestinal manifestation or as an adverse
reaction to 5-ASA therapy. Such occurrence is well reported
and documented, with several cases described in literature
reports [54, 94–100]. 5-ASA-associated myocarditis is a
rare but potentially life-threatening manifestation, generally
occurring 2–4 weeks after the initial exposure to the drug
[94]. However, the time between the first exposure and
myocarditis occurrencemight be delayed, especially in case of
concomitant steroids therapy [97, 98]. Drugs can determinate
myocarditis as a direct toxic agent or by inducing a hyper-
sensitivity reaction [101]. The mechanism by which 5-ASA
can trigger myocarditis is likely to be a humoural-mediated
hypersensitivity reaction [101], thus similar to the one already
described for penicillin and tricyclic antidepressants [97, 99,
102]. Several recent findings support this hypothesis: first,
inflammation worsens if 5-ASA is reintroduced during the
acute phase; second the symptom resolution occurs within
one week after drug discontinuation; third myocardium
biopsy shows eosinophilic infiltration [95, 96, 98, 103].
4.4. Adherence. Adherence to 5-ASA treatment represents
an important source of concern. According to reports from
clinical trials in IBD patient, adherence rates range between
70% and 95%. In the normal clinical practice, however,
nonadherence rates (defined as taking less than 80% of
prescribed medication) range between 40% and 72% [104].
Adherence is a composite and multifactorial issue, in which
a variety of factors play a role, including lack of insight into
illness, perceptions and beliefs about the illness, treatment of
asymptomatic disease, forgetfulness, and, last but not least,
poor physician-patient relationship. A cohort study of 99 UC
patients in remission demonstrated a considerable impact of
adherence on clinical recurrence, with a fivefold greater risk
of recurrence in nonadherent patients [104].
5. Five-ASA Shadows and Lights
Thirty years have passed since 5-ASA (in the form of sul-
fasalazine) was introduced into the management of IBD, and
today it remains the backbone of treatment of UC for achiev-
ing and maintaining remission [5]. From the time of the
launch onto the market until now many efforts have been
made to develop new 5-ASA formulation acting, on the one
hand, to improve its release in the colon by oral formulations
and, on the other, to reduce the dosing schedule from a
multiple- to a once-daily dosing [5]. The optimal number of
5-ASA doses per day for treatingmild-to-moderate UC is still
an area of some discussion.Theuse ofmultiple daily dosing (4
times per day) was at first based on the pharmacokinetics of
sulfasalazine, where peaks and troughs of drug plasma levels
occurred quickly. However, upon sulfasalazine administra-
tion, 30% of patients experienced adverse events and 50%
stopped medical therapy [105]. Currently, several 5-ASA for-
mulations are designed with once-daily administration, such
as 5-ASA-Multi Matrix System, which is used for induction
therapy, and prolonged-release 5-ASA granules, which are
approved for the treatment of acute episodes and the main-
tenance of remission [106]. Systemic concentration measure-
ments, which allow understanding the drug’s distribution
within the body, are used for a variety of drugs to estimate
therapeutic effects. However, a series of 5-ASA peculiarities
may impair the efficacy of this type of diagnostic test. 5-ASA
acts topically and only low levels are released into the plasma
via the colonic mucosa, thus making it difficult to relate
mucosal and plasma concentrations. In their recent review on
5-ASA formulations used for UC therapies, Lichtenstein et al.
pointed out that mucosal biopsies could be used to establish
colonic distribution and to predict clinical efficacy [107].
The association between high mucosal 5-ASA levels and
low disease activity has been shown in several studies, and
interindividual variability in these levels has been proposed
to be a useful tool to explain the differences observed in
clinical effectiveness [108, 109]. A relationship between dose
and response has been analysed recently in two systematic
reviews from the Cochrane database both in induction and
maintenance of remission therapies [64, 110]. Oral 5-ASA
administered once daily has been found to be as effective as
conventional dosing (twice or three times daily) for induction
in mild-to-moderately active UC and for maintenance of
remission in quiescent disease state. In patients with mild
UC a dosage of 4 to 4.8 g/day does not appear to provide any
additional benefit over a dosage of 2 to 2.4 g/day. However,
patients with severe symptoms andmoderate UCmay benefit
from an initial dosage of 4 to 4.8 g/day [110]. Recently, the
Assessing the Safety and Clinical Efficacy of a New Dose
of 5-ASA (ASCEND) III study suggested the advantage of
the 4.8 g/day dose for patients affected by moderate disease
treated previously with corticosteroids, oral mesalamines at
low doses, rectal therapies, or multiple UC medications [111].
Few dose ranging studies for maintenance therapy have been
performed so far, thus limiting the conclusions that can be
drawn. In general it appears that patients with extensive UC
or with frequent relapses may benefit from a higher dose of
maintenance therapy [64]. Further studies are required to
elucidate fully this topic.
Another important aspect among 5-ASA indications that
is subject of debate is the chemoprotective role of the drug
against the CRC as a consequence of IBD. Preclinical in vitro
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studies have shown that 5-ASA has antineoplastic properties
by reducing inflammation and oxidative stress, inhibiting
cell proliferation and promoting cell death, thus indicating
that 5-ASA may not only act on the inflammatory cells,
but also target cancer cells and inhibit pathways that are
involved in sporadic CRC cell growth and survival [8, 9, 112].
The first report showing a reduction in CRC risk associated
with 5-ASA use in UC patients was published in 1994 [113].
Since then, several observational studies have reported con-
tradictory data about the chemoprotective action of 5-ASA;
unfortunately, even data coming from meta-analyses are
difficult to interpret because of the selection bias and the
heterogeneity among the studies analysed [114–116]. Thereby,
while the favourable effects of 5-ASA on CRC prevention are
biologically conceivable and validated in vitro, the clinical
confirmation of the relationship between the use of 5-ASA
and the reduction of the risk CRC is still insufficient and
requires further investigation.
6. Outlook on 5-ASA in Paediatry
A large number of preclinical and clinical studies testify
the continuous attention on 5-ASA and on finding new
therapeutic indications. In this respect, the possibility to use
5-ASA in the treatment of IBD in the paediatric population
is a relevant issue [117]. The main problem in the treatment
of paediatric patients is the lack of information on the
paediatric use of most drugs that prevent often the optimal
treatment of the patients. This occurs in the treatment of
paediatric IBD, where few of the therapies used to induce
and maintain its remission have been studied in paediatric
clinical trials, to the point that most of information has
had to be extrapolated from adult data [117]. Children need
individualised therapies that take several factors into con-
sideration including the child’s age and size and the specific
disease manifestations such as location of inflammation,
duration, and prior response to therapy. Drug dosages also
must be adjusted, based upon the child’s pharmacodynamic
parameters. For the treatment of mild-to-moderate UC and
CD in children, in most cases 5-ASA is the initial therapy
[117]. The strength of the administration to children of 5-
ASA versus other treatments available lies in its low risk
profile although the safety of 5-ASA, which is well established
in the adult population, lacks confirmation in children. In
addition, a number of issues remain to be solved. The dosage
for children is extrapolated on a per-kilogram basis from
data in adults. The number of treatments required per day
and the frequency of administration for achieving efficacy
(3-4 times per day) make compliance with 5-ASA very
difficult in paediatric patients. A recent study conducted in
clinical practice centres across North America and Europe
reported that oral, delayed-release 5-ASA is an effective
treatment in children with mild-to-moderate UC treated
for 6 weeks [118]. Of notice, low and high doses of 5-ASA
were similarly effective and well tolerated, with only few
patients discontinuing treatment owing to an adverse effect
[118]. Another study showed that a daily treatment of a 5-
ASA is safe and efficacious in children and adolescents with
ulcerative proctitis, the initialmanifestation in a large portion
of newly diagnosed UC cases [119]. Among the clinical trials
found on https://clinicaltrial.gov/ (a service of the USA
National Institute of Health) that have been proposed and
conducted in the paediatric population to construct a model
for an individualised 5-ASA treatment to improve the current
outcomes, notable is the “Predicting Response to Standard-
ized Pediatric ColitisTherapy” (PROTECT) study.This study
is still ongoing and intends to evaluate the outcome of a
best practices protocol (5-ASA alone and in combination
with the corticosteroid prednisone) for the treatment of
children newly diagnosed with UC.This study has as primary
outcome the remission of the disease after one year of treat-
ment. Moreover, it aims to stratify patients based on clinical,
genetic, and immunologic tests in order to determine the
impact of these parameters on the primary outcome and
to understand the interpatients variability in response to
therapy. The elucidation of the reason of interpatient vari-
ability in the response to therapy that should be achieved
through the PROTECT study, as well as other studies still
currently in progress, may open new perspectives, with the
aim tomaximise the benefit of 5-ASA therapy in children thus
reducing the administration of corticosteroids, more potent
but also more toxic, and/or the need for colectomy.
7. Conclusion
In several countries, IBD has been increasing in incidence
and prevalence with the highest rates in USA, Canada, and
Europe [120]. Despite recent therapeutic advances, morbidity
is still high and may affect patient’s quality of life. Five-ASA
is the first line treatment of patients with UC from mild to
moderate, used with the intent to induce remission, promote
mucosal healing, and minimise steroid use and its toxicity.
Unfortunately, about 30% of patients treated with 5-ASA are
considered not responders, because of allergy, intolerance,
underdosage, refractoriness to the treatment, and the need of
switching their therapy tomore potent and toxicmedications.
New strategies are under investigation to avoid this issue.
For example, even in the absence of any prospective study,
combination therapy of different formulation of 5-ASA (oral
and topical)may be considered in patientswho fail to respond
to the monotherapy before switching to steroids. The safety
profile is indeed one of the strengths of 5-ASA and may
account for its usage in specific populations. In this regard
new clinical trials have been carried out on these patients and
the results may shed light on optimising 5-ASA therapy.
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